ChemicalBook Product Catalog API Antineoplastic agents Other antineoplastic Drugs Onartuzumab

Onartuzumab

Product NameOnartuzumab
CAS1133766-06-9
MF
MW0
EINECS
MOL FileMol File

Chemical Properties

form	Liquid
color	Colorless to light yellow

Usage And Synthesis

Description

Onartuzumab is a monoclonal antibody that blocks the binding of HGF to the MET receptor.

Uses

Onartuzumab (MetMAb) is a unique, humanized and affinity-matured monovalent (one-armed) monoclonal antibody against the MET receptor. Onartuzumab potently inhibits HGF binding and receptor phosphorylation and signaling. Onartuzumab has antibody-like pharmacokinetics and antitumor activity[1].

Clinical Use

Onartuzumab is ineffective in improving clinical outcomes in (i) combination with current first-line chemotherapy in advanced nonsquamous cell NSCLC , (ii) combination with erlotinib in previously treated stage IIIB or IV NSCLC patients (Phase III) , and (iii) combination with platinum-doublet chemotherapy in advanced squamous cell NSCLC (Phase II) .

in vivo

Onartuzumab (30 mg/kg, IP, twice a week for 2 mouth) suppresses tumor growth^[3].

Animal Model:	Human HGF-transgenic SCID mice implanted with BxPC3 tumor cells, nude (nu/nu) mice implanted with KP4 human pancreatic xenograft tumor cells^[3]
Dosage:	30 mg/kg
Administration:	IP, twice a week for 2 mouth
Result:	Suppressed tumor growth, but did not affect the mean in vivo human HGF levels.

Animal Model:	U-87 MG tumor-bearing mice^[3]
Dosage:	30 mg/kg
Administration:	IP, once
Result:	Resulted in profound TGI (tumor growth inhibition) with 4/10 mice demonstrating a partial response (>50% reduction in tumor size) and 6/10 mice demonstrating a complete response (100% tumor regression).

References

[1] Merchant M, et al. Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent. Proc Natl Acad Sci U S A. 2013 Aug 6;110(32):E2987-96. DOI:10.1073/pnas.1302725110
[2] Prell RA, et al. Placental and Fetal Effects of Onartuzumab, a Met/HGF Signaling Antagonist, When Administered to Pregnant Cynomolgus Monkeys. Toxicol Sci. 2018 Sep 1;165(1):186-197. DOI:10.1093/toxsci/kfy141

Onartuzumab Supplier

Onartuzumab manufacturers

Related Product Information

Send Inquriy